Skip to main content

Pediatric Osteosarcoma of Extremities: a 15-year Experience from a Tertiary Care Cancer Center in Upper Egypt

Research Abstract
Aim: To assess the outcome and determine predictors of survival in pediatric patients with osteosarcoma of the extremities treated with a unified chemotherapy protocol at a single institution over a fifteen-year period. Methods: We performed a retrospective analysis of medical records of 48 pediatric patients with histologically-verified osteosarcoma of the extremities diagnosed at South Egypt Cancer Institute and received treatment between January 2001 and December 2015. Results: With a median follow-up of 61 months for the entire cohort, estimates of Overall Survival (OS) for 3 and 5-year were 50.9% & 42.1%, respectively. While the estimates of OS for 3 and 5-year in the non-metastatic group were 79% & 65.2%, respectively. In the multivariable analysis, both metastatic disease at diagnosis and poor response to chemotherapy retained their statistical significance as independent predictors for Event Free Survival (EFS). Whereas for OS, a metastatic disease at diagnosis remained as the lone predictor of a dismal outcome, whilst a poor response to chemotherapy became marginally associated with an inferior outcome. Conclusion: In Upper Egypt, whereas slightly less than two-thirds of children with localized osteosarcoma of extremities survives their disease, metastasis at presentation remains the key predictor of dismal survival outcomes.
Research Authors
Ahmed Mohammed Morsy,
Marwa I. Abdelgawad,
Badawy M. Ahmed,
Khalid M. Rezk,
Amir M. Aboelgheit,
Islam K. Ramadan,
Hosam Eldein M. Kamel,
Doaa M. Fouad,
Rania A. Herdan,
Shimaa H. Shabaan,
Hanan A. Eltyb
Research Department
Research Journal
Journal of Pediatric Hematology/Oncology
Research Pages
e371–e383
Research Publisher
Wolters Kluwer Health, Inc.
Research Rank
1
Research Vol
41(6)
Research Website
https://journals.lww.com/jpho-online/Abstract/2019/08000/Pediatric_Osteosarcoma_of_Extremities__A_15_year.23.aspx
Research Year
2019

epidural dexmedetomidine infusion for
perioperative analgesia in patients undergoing
abdominal cancer surgery: randomized trial

Research Abstract
NULLTo assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. Methods: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine )=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/ of bupivacaine 0.1% + dexmedetomidine, 0.5 μg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS painةscore were evaluated. Results: The cumulative morphine consumption was significantly reduced in group bupivacaine+ dexmedetomidine compared with group bupivacaine: mean ± SD of 10.40±5.16 mg vs23.23±8.37mg with an estimated difference (95% CI) of –12.83 (−16.43, –9.24), (P0.001(.The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, P0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine:mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of −0.8(−1, –0.86), (P0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference(95% CI) of −1.1 (−1.27, – 0.89), (P0.001), respectively. Conclusion: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Research Authors
Diab Fuad hetta1
Khaled Mohamed Fares1
abualauon Mohamed
abedalmohsen2
amani hassan abdelWahab2
ghada Mohammed abo
elfadl2
Wesam nashat ali2
Research Journal
Journal of Pain Research 2018 Nov;
Research Pages
pp. 2675–2685
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018

epidural dexmedetomidine infusion for
perioperative analgesia in patients undergoing
abdominal cancer surgery: randomized trial

Research Abstract
NULLTo assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. Methods: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine )=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/ of bupivacaine 0.1% + dexmedetomidine, 0.5 μg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS painةscore were evaluated. Results: The cumulative morphine consumption was significantly reduced in group bupivacaine+ dexmedetomidine compared with group bupivacaine: mean ± SD of 10.40±5.16 mg vs23.23±8.37mg with an estimated difference (95% CI) of –12.83 (−16.43, –9.24), (P0.001(.The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, P0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine:mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of −0.8(−1, –0.86), (P0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference(95% CI) of −1.1 (−1.27, – 0.89), (P0.001), respectively. Conclusion: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Research Authors
Diab Fuad hetta1
Khaled Mohamed Fares1
abualauon Mohamed
abedalmohsen2
amani hassan abdelWahab2
ghada Mohammed abo
elfadl2
Wesam nashat ali2
Research Journal
Journal of Pain Research 2018 Nov;
Research Pages
pp. 2675–2685
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018

epidural dexmedetomidine infusion for
perioperative analgesia in patients undergoing
abdominal cancer surgery: randomized trial

Research Abstract
NULLTo assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. Methods: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine )=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/ of bupivacaine 0.1% + dexmedetomidine, 0.5 μg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS painةscore were evaluated. Results: The cumulative morphine consumption was significantly reduced in group bupivacaine+ dexmedetomidine compared with group bupivacaine: mean ± SD of 10.40±5.16 mg vs23.23±8.37mg with an estimated difference (95% CI) of –12.83 (−16.43, –9.24), (P0.001(.The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, P0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine:mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of −0.8(−1, –0.86), (P0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference(95% CI) of −1.1 (−1.27, – 0.89), (P0.001), respectively. Conclusion: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Research Authors
Diab Fuad hetta1
Khaled Mohamed Fares1
abualauon Mohamed
abedalmohsen2
amani hassan abdelWahab2
ghada Mohammed abo
elfadl2
Wesam nashat ali2
Research Journal
Journal of Pain Research 2018 Nov;
Research Pages
pp. 2675–2685
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018

epidural dexmedetomidine infusion for
perioperative analgesia in patients undergoing
abdominal cancer surgery: randomized trial

Research Abstract
NULLTo assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. Methods: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine )=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/ of bupivacaine 0.1% + dexmedetomidine, 0.5 μg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS painةscore were evaluated. Results: The cumulative morphine consumption was significantly reduced in group bupivacaine+ dexmedetomidine compared with group bupivacaine: mean ± SD of 10.40±5.16 mg vs23.23±8.37mg with an estimated difference (95% CI) of –12.83 (−16.43, –9.24), (P0.001(.The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, P0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine:mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of −0.8(−1, –0.86), (P0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference(95% CI) of −1.1 (−1.27, – 0.89), (P0.001), respectively. Conclusion: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Research Authors
Diab Fuad hetta1
Khaled Mohamed Fares1
abualauon Mohamed
abedalmohsen2
amani hassan abdelWahab2
ghada Mohammed abo
elfadl2
Wesam nashat ali2
Research Journal
Journal of Pain Research 2018 Nov;
Research Pages
pp. 2675–2685
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018

epidural dexmedetomidine infusion for
perioperative analgesia in patients undergoing
abdominal cancer surgery: randomized trial

Research Abstract
NULLTo assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. Methods: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine )=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/ of bupivacaine 0.1% + dexmedetomidine, 0.5 μg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS painةscore were evaluated. Results: The cumulative morphine consumption was significantly reduced in group bupivacaine+ dexmedetomidine compared with group bupivacaine: mean ± SD of 10.40±5.16 mg vs23.23±8.37mg with an estimated difference (95% CI) of –12.83 (−16.43, –9.24), (P0.001(.The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, P0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine:mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of −0.8(−1, –0.86), (P0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference(95% CI) of −1.1 (−1.27, – 0.89), (P0.001), respectively. Conclusion: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Research Authors
Diab Fuad hetta1
Khaled Mohamed Fares1
abualauon Mohamed
abedalmohsen2
amani hassan abdelWahab2
ghada Mohammed abo
elfadl2
Wesam nashat ali2
Research Journal
Journal of Pain Research 2018 Nov;
Research Member
Khaled Mohamed Fares Ali
Research Pages
pp. 2675–2685
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018

epidural dexmedetomidine infusion for
perioperative analgesia in patients undergoing
abdominal cancer surgery: randomized trial

Research Abstract
NULLTo assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery. Methods: Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine )=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/ of bupivacaine 0.1% + dexmedetomidine, 0.5 μg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS painةscore were evaluated. Results: The cumulative morphine consumption was significantly reduced in group bupivacaine+ dexmedetomidine compared with group bupivacaine: mean ± SD of 10.40±5.16 mg vs23.23±8.37mg with an estimated difference (95% CI) of –12.83 (−16.43, –9.24), (P0.001(.The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine: median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, P0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine:mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of −0.8(−1, –0.86), (P0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference(95% CI) of −1.1 (−1.27, – 0.89), (P0.001), respectively. Conclusion: Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Research Authors
Diab Fuad hetta1
Khaled Mohamed Fares1
abualauon Mohamed
abedalmohsen2
amani hassan abdelWahab2
ghada Mohammed abo
elfadl2
Wesam nashat ali2
Research Journal
Journal of Pain Research 2018 Nov;
Research Member
Research Pages
pp. 2675–2685
Research Publisher
NULL
Research Rank
1
Research Vol
NULL
Research Website
NULL
Research Year
2018

Activated and Memory T Lymphocytes in Children with Gaucher
Disease

Research Abstract
Gaucher disease (GD) is the most prevalent lysosomal storage disorder. Gaucher disease is associated with remarkable alterations in the immune system, and GD patients are more susceptible to infections and are at a higher risk of developing autoimmune disorders and malignancies. In a case–control study, we used three-color flow cytometric immunophenotyping for determination of the frequency of lymphocyte subpopulations and activated T lymphocytes among 18 children with GD1 under enzyme replacement therapy managed in Assiut University Hospitals. We found significant increases in the frequencies of total lymphocytes, CD19?, CD3?, CD4?, and CD8? in children with GD1 when compared to healthy control. The frequencies of activated T lymphocytes (CD3?HLA-DR?), activated T-helper cells (CD4?HLA-DR?), and activated T-suppressor/cytotoxic cells (CD8?HLA-DR?) were significantly higher in GD1 as compared to healthy children. Our data show that the increased proportion of activated T lymphocytes in children with GD1 raises the issue of their possible involvement in the pathogenesis of the immune dysfunction seen in these patients. Our data suggested that the activated T lymphocytes could play a role in the clinical course of GD1. The relationship of these cells to immune disorders in GD1 children remains to be determined.
Research Authors
Asmaa M. Zahran • Azza A. Eltayeb • Khalid I. Elsayh
• Khaled Saad • Faisal-Alkhateeb Ahmad • Ahmad I. M. Ibrahim
Research Journal
Archivum Immunologiae et Therapiae Experimentalis
Research Pages
263-269
Research Publisher
springer
Research Rank
1
Research Vol
65(3)
Research Website
NULL
Research Year
2017

Activated and Memory T Lymphocytes in Children with Gaucher
Disease

Research Abstract
Gaucher disease (GD) is the most prevalent lysosomal storage disorder. Gaucher disease is associated with remarkable alterations in the immune system, and GD patients are more susceptible to infections and are at a higher risk of developing autoimmune disorders and malignancies. In a case–control study, we used three-color flow cytometric immunophenotyping for determination of the frequency of lymphocyte subpopulations and activated T lymphocytes among 18 children with GD1 under enzyme replacement therapy managed in Assiut University Hospitals. We found significant increases in the frequencies of total lymphocytes, CD19?, CD3?, CD4?, and CD8? in children with GD1 when compared to healthy control. The frequencies of activated T lymphocytes (CD3?HLA-DR?), activated T-helper cells (CD4?HLA-DR?), and activated T-suppressor/cytotoxic cells (CD8?HLA-DR?) were significantly higher in GD1 as compared to healthy children. Our data show that the increased proportion of activated T lymphocytes in children with GD1 raises the issue of their possible involvement in the pathogenesis of the immune dysfunction seen in these patients. Our data suggested that the activated T lymphocytes could play a role in the clinical course of GD1. The relationship of these cells to immune disorders in GD1 children remains to be determined.
Research Authors
Asmaa M. Zahran • Azza A. Eltayeb • Khalid I. Elsayh
• Khaled Saad • Faisal-Alkhateeb Ahmad • Ahmad I. M. Ibrahim
Research Department
Research Journal
Archivum Immunologiae et Therapiae Experimentalis
Research Member
Research Pages
263-269
Research Publisher
springer
Research Rank
1
Research Vol
65(3)
Research Website
NULL
Research Year
2017

Activated and Memory T Lymphocytes in Children with Gaucher
Disease

Research Abstract
Gaucher disease (GD) is the most prevalent lysosomal storage disorder. Gaucher disease is associated with remarkable alterations in the immune system, and GD patients are more susceptible to infections and are at a higher risk of developing autoimmune disorders and malignancies. In a case–control study, we used three-color flow cytometric immunophenotyping for determination of the frequency of lymphocyte subpopulations and activated T lymphocytes among 18 children with GD1 under enzyme replacement therapy managed in Assiut University Hospitals. We found significant increases in the frequencies of total lymphocytes, CD19?, CD3?, CD4?, and CD8? in children with GD1 when compared to healthy control. The frequencies of activated T lymphocytes (CD3?HLA-DR?), activated T-helper cells (CD4?HLA-DR?), and activated T-suppressor/cytotoxic cells (CD8?HLA-DR?) were significantly higher in GD1 as compared to healthy children. Our data show that the increased proportion of activated T lymphocytes in children with GD1 raises the issue of their possible involvement in the pathogenesis of the immune dysfunction seen in these patients. Our data suggested that the activated T lymphocytes could play a role in the clinical course of GD1. The relationship of these cells to immune disorders in GD1 children remains to be determined.
Research Authors
Asmaa M. Zahran • Azza A. Eltayeb • Khalid I. Elsayh
• Khaled Saad • Faisal-Alkhateeb Ahmad • Ahmad I. M. Ibrahim
Research Journal
Archivum Immunologiae et Therapiae Experimentalis
Research Pages
263-269
Research Publisher
springer
Research Rank
1
Research Vol
65(3)
Research Website
NULL
Research Year
2017
Subscribe to